Search

everythinglearnresearchcommunity

for

Search:↓

A humanized IL-2 fusion protein boosts T regulatory cells and helps control hair loss in Alopecia Areata.

Tildrakizumab showed limited effectiveness in treating chronic alopecia areata in a small group of patients.

Upadacitinib improved multiple immune-related conditions in one patient.

Eribulin-based chemotherapy is more effective and has fewer side effects for advanced triple-negative breast cancer.

The combination of high-dose toremifene and capecitabine was effective for advanced recurrent breast cancer.

Aumolertinib is effective and well-tolerated for treating advanced lung cancer with EGFR mutations.

The document concludes that understanding how the skin's immune system and inflammation work is complex and requires more research to improve treatments for skin diseases.

Anticancer drugs are increasingly found in surface waters, and their long-term environmental effects are not well understood, requiring better testing methods.

Teriflunomide helps reduce multiple sclerosis symptoms and is safe for most patients.

Memory T cells in the skin balance staying put and moving into the blood, clustering around hair follicles, and increasing in number after infection.

Transplant success has improved with better immunosuppressive drugs and donor matching.

Cancer therapy can cause various skin problems, including hair loss, skin darkening, painful hand-foot syndrome, and severe skin damage.

COVID-19 can cause skin issues like rashes and "COVID toes," and people with skin conditions should adjust their treatments if they get the virus.

Tissue-resident memory T cells can protect against infections and cancer but may also contribute to autoimmune diseases.

Targeted cancer therapies have a significant but lower risk of causing hair loss compared to chemotherapy.

The document concludes that treatment for cutaneous T-cell lymphoma should be customized to each patient's disease stage, balancing benefits and side effects, with no cure but many patients living long lives.

Female donor to male recipient sex mismatch and positive ACA-IgG are key risk factors for vitiligo and alopecia areata in chronic GvHD patients.

Teriflunomide effectively reduces relapses and disability in MS and has a manageable safety profile.

Cell therapy shows promise for treating severe psoriasis but needs more research to confirm safety and effectiveness.

Bendamustine, often combined with other drugs, is effective and less toxic for certain blood cancers, but less effective for young, fit patients with CLL.

A woman's ovarian tumor causing high testosterone was successfully removed, and her symptoms improved.

Hair thinning is a common but generally mild and reversible side effect of teriflunomide in multiple sclerosis patients.

Newborn screening and gene therapy are expected to improve outcomes for Omenn syndrome patients.

Certain drugs may cause vitiligo, so patients should be monitored.

New cancer treatments are less harmful to hair but can still cause hair loss, color, shape, and growth changes.

A man got six skin cancers within a year after a cell transplant for leukemia but was cancer-free 32 months later; skin checks are important post-transplant.

Different types of alopecia cause hair loss due to immune system issues, with some allowing regrowth and others causing permanent loss.

Early recognition of skin issues in immunocompromised patients is crucial for better outcomes.

64 drugs can cause hair loss, needing better monitoring and updated labels.

Electrical stimulation with a low-calorie diet reduces appetite, weight, and blood pressure in obese people with sleep apnea.